SAN DIEGO, Oct. 4, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, today announced that subsidiary HempMeds® will be participating in the 4th annual Boston CWCBE from October 5-6, 2017.
Members of Medical Marijuana, Inc.’s executive team will be participating in the “Investing in Publicly Traded Companies” panel taking place on Thursday October 5, 2017 at 3:30 p.m. in room 109 at the John B. Hynes Convention Center in Boston. This panel will include the most up-to-date information about investing in publicly traded cannabis companies. Speakers on the panel include parent company, Medical Marijuana, Inc. CEO, Dr. Stuart Titus, Dean Petkanas of portfolio company, KannaLife Sciences, and George Anastassov of investment company AXIM Biotechnologies.
HempMeds® will also be participating in the “Cannabis Patient and Care Giver Panel” taking place at 10 a.m. in room 104 at the John B. Hynes Convention Center. This panel will be featuring the families and caregivers of consumers who use HempMeds® products. Panelists include: The Pagano family and their emergency room nurse Gina Caracciolo, Casandra Stephans and her daughter Lillyann Baker, HempMeds® Mexico General Manager and father of an epilepsy patient Raul Elizalde, and longtime cannabis advocate, Penny Howard. The panelists will be discussing their experiences with devastating disabilities and their choice to use cannabis as treatment for their children.
“We are extremely proud to be once again participating in another Cannabis World Congress event,” said Dr. Titus. “We know that with our extensive background and knowledge in the field of cannabis and cannabidiol research that our audiences will be informed with interesting information and some clinical data on both the botanical as well as pharmaceutical side. Those interested in exploring cannabidiol products, as well as those interested in investing in publicly traded cannabis companies will greatly benefit from attending the panel sessions that HempMeds® will be participating in.”
Dr. Titus will be giving a pre-show interview around the investing in the industry topic on the Money Matters Boston Radio Show, on Wednesday, October 4, 2017. Listen live here.
In addition to participating in these two panel sessions, HempMeds® will also have a booth at spot #212 throughout the entirety of the convention. Those interested in HempMeds® quality CBD lifestyle products, like Real Scientific Hemp Oil™ (RSHO™), are encouraged to stop by the booth to speak with a representative.
HempMeds® offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMeds® is a corporate portfolio company of Medical Marijuana, Inc. (OTC:MJNA) and the Company’s exclusive master distributor and contracted marketing company. In addition to handling sales and distribution, HempMeds® is the communication hub for the Medical Marijuana Inc. portfolio of companies.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here.
Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
Public Relations Contact:
Chief Executive Officer
P: 888-829- 0070